STOCK TITAN
  1. Home
  2. News
  3. HROW

Harrow, Inc. - HROW STOCK NEWS

Welcome to our dedicated page for Harrow news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow stock.

Harrow Health, Inc. (NASDAQ: HROW) is a leading eyecare pharmaceutical company dedicated to developing, producing, and distributing medications that address unmet medical needs, primarily within the United States. The company’s core business revolves around the creation of ophthalmology-based formulations, providing both sterile and non-sterile compounded medications to physicians and patients.

Harrow Inc. is at the forefront of innovative therapeutics, focusing on the treatment of ocular surface diseases. The firm's product portfolio includes prominent drug candidates such as SURF-100 and SURF-200, which are topical eye drops; SURF-300, an oral capsule aimed at treating ocular surface diseases and dry eye disease (DED) symptoms; and Klarity drops, designed for the protection and rehabilitation of ocular surface pathology in DED patients.

Additionally, Harrow, Inc. is known for its non-intravenous sedation and anesthesia products for various medical procedures. MELT-100, for instance, is a sublingual drug facilitating conscious sedation during cataract surgery, and MAY-66 is utilized for alleviating symptoms associated with Peyronie’s disease.

Harrow Health's commitment goes beyond innovation; it strives to improve accessibility and affordability of eyecare pharmaceuticals for millions of Americans. Through strategic partnerships and ongoing projects, Harrow, Inc. continues to enhance its capabilities in the eyecare sector, firmly positioning itself as a trusted name among U.S. eyecare professionals.

Stay updated with the latest developments, financial reports, and news on Harrow, Inc. to understand how this company is shaping the future of ophthalmic care.

News

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

Rhea-AI Summary
Harrow (Nasdaq: HROW) launches VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both the signs and symptoms of dry eye disease (DED) in the U.S. VEVYE offers rapid onset with clinically and statistically meaningful improvement beginning as early as 15 days, with sustained improvement over 56 weeks. VEVYE patients have access to a 100% money-back guarantee program. The drug is powered by a unique combination of cyclosporine and a water-free semifluorinated alkane delivery vehicle, solving an unmet need for eyecare professionals treating the tens of millions of American chronic dry eye disease sufferers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News

Melt Pharmaceuticals Provides Corporate Update

Rhea-AI Summary
Melt Pharmaceuticals, Inc. (Melt) provided a corporate update, announcing the success of MELT-300 in its Phase 2 Pivotal Efficacy and Safety Study for procedural sedation in cataract surgery. The non-IV, non-opioid tablet, using Catalent Inc.'s fast-dissolving Zydis® delivery technology, is expected to begin Phase 3 program activities in the first quarter of 2024. Additionally, Melt settled its debt with its largest shareholder, Harrow, Inc. (Nasdaq: HROW), and secured funding for the Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
-
News

Harrow Partners with Leading Healthcare Market Access Technology Platforms

Rhea-AI Summary
Harrow (Nasdaq: HROW) has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED). The partnerships with PhilRx, Apollo Care, and PARx Solutions aim to simplify the prior authorization process, establish copay program deployment, and help prescribers overcome challenges. Harrow's commitment to patient access and innovative, affordable ophthalmic pharmaceutical products is reflected in its market access program for VEVYE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
partnership
News

Harrow Completes Transfer of the TRIESENCE® New Drug Application

Rhea-AI Summary
Harrow (Nasdaq: HROW) has completed the transfer of the New Drug Application (NDA) for TRIESENCE, a synthetic corticosteroid used for various eye conditions, ahead of the previously agreed date. The company has also acquired the U.S. commercial rights to TRIESENCE and is making progress in manufacturing commercial batches. Harrow is implementing market access, marketing, inventory management, and brand-leveraging strategies to re-launch TRIESENCE in the U.S., showing a promising outlook for the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
News

Harrow to Present at Two Investor Conferences in November

Rhea-AI Summary
Harrow (Nasdaq: HROW) Announces Participation in Upcoming Conferences, BTIG 3rd Annual Ophthalmology Day and Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
-
News

Harrow Announces Third Quarter 2023 Financial Results

Rhea-AI Summary
Harrow (Nasdaq: HROW) - Harrow, a leading U.S. eyecare pharmaceutical company, reported record revenues of $34.3 million in the third quarter of 2023, marking a 50% increase over the prior-year revenues. The company also announced a GAAP net loss of $(4.4 million) and an adjusted EBITDA of $9.2 million, representing a 270% increase over the prior-year quarter. Additionally, Harrow completed the transfer of NDAs and launched several products in the U.S., including FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE®. CEO Mark L. Baum commented on the results, highlighting the exceptional performance of the IHEEZO® launch and the substantial increase in unit demand in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.01%
Tags
earnings
News

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023

Rhea-AI Summary
Harrow, a leading U.S. eyecare pharmaceutical company, will release its financial results for Q3 2023 on November 13, 2023. The company will also provide a business update during a conference call and live webcast at 4:45 p.m. Eastern Time. Participants can access the webcast on harrow.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
earnings
-
News

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Rhea-AI Summary
Harrow has completed the transfer of New Drug Applications for several eyecare pharmaceutical products and has launched them in the U.S. market. The company aims to increase brand awareness and sales through its marketing and sales teams. Product orders can be made through Cardinal's Cordlogistics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
-
News

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

Rhea-AI Summary
Harrow (Nasdaq: HROW) changes its corporate name to Harrow, Inc. to align with its strategic focus on eyecare pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
News

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

Rhea-AI Summary
Melt Pharmaceuticals enters exclusive development and license agreement with Catalent for MELT-300, a sublingual formulation for procedural sedation during cataract surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none

FAQ

What is the current stock price of Harrow (HROW)?

The current stock price of Harrow (HROW) is $36.34 as of January 3, 2025.

What is the market cap of Harrow (HROW)?

The market cap of Harrow (HROW) is approximately 1.3B.

What does Harrow, Inc. specialize in?

Harrow, Inc. specializes in developing, producing, and selling ophthalmic pharmaceutical products and compounded medications for unmet medical needs in the U.S.

What are some key products of Harrow, Inc.?

Key products include SURF-100, SURF-200, SURF-300, Klarity drops, MELT-100, and MAY-66, which cater to various ocular surface diseases and medical procedures.

What is the significance of SURF-300?

SURF-300 is an oral capsule designed to treat patients suffering from ocular surface diseases and symptoms of dry eye disease (DED).

How does MELT-100 benefit patients?

MELT-100 is administered sublingually for conscious sedation during cataract surgery, providing a non-intravenous sedation option.

Who are the primary customers of Harrow, Inc.?

The primary customers are U.S. eyecare professionals and their patients, benefiting from Harrow, Inc.'s comprehensive portfolio of affordable pharmaceutical products.

What makes Harrow, Inc. unique in the eyecare pharmaceutical sector?

Harrow, Inc. stands out due to its focus on unmet medical needs, innovative product portfolio, and commitment to accessibility and affordability in the ophthalmic care market.

How does Harrow, Inc. contribute to the treatment of dry eye disease (DED)?

Products like SURF-300 and Klarity drops are specifically designed to treat and manage symptoms of dry eye disease, protecting and rehabilitating the ocular surface.

Where is Harrow, Inc. based?

Harrow, Inc. operates primarily in the United States, serving the American market with its pharmaceutical innovations.

What recent achievements has Harrow, Inc. made?

Recent achievements include the development and commercialization of various therapeutics for ocular surface diseases and advancements in non-intravenous sedation products.

How can investors stay updated with Harrow, Inc.'s latest news?

Investors can stay updated by following financial reports, press releases, and news updates provided by the company and credible financial news sources.
Stock HROW logo
Harrow, Inc.

Nasdaq:HROW

HROW Rankings

#2315 Ranked by Market Cap
N/A Ranked by Dividends

HROW Stock Data

1.31B
30.81M
13.49%
59.29%
8.33%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NASHVILLE